ATE373676T1 - Verfahren zur aktivierung von sgk durch phosphorylierung. - Google Patents

Verfahren zur aktivierung von sgk durch phosphorylierung.

Info

Publication number
ATE373676T1
ATE373676T1 AT99961205T AT99961205T ATE373676T1 AT E373676 T1 ATE373676 T1 AT E373676T1 AT 99961205 T AT99961205 T AT 99961205T AT 99961205 T AT99961205 T AT 99961205T AT E373676 T1 ATE373676 T1 AT E373676T1
Authority
AT
Austria
Prior art keywords
sgk
arg
amino acid
phosphorylation
indicates
Prior art date
Application number
AT99961205T
Other languages
English (en)
Inventor
Philip Cohen
Takayasu Kobayashi
Maria Deak
Original Assignee
Univ Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9919676.8A external-priority patent/GB9919676D0/en
Application filed by Univ Dundee filed Critical Univ Dundee
Application granted granted Critical
Publication of ATE373676T1 publication Critical patent/ATE373676T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99961205T 1998-12-14 1999-12-14 Verfahren zur aktivierung von sgk durch phosphorylierung. ATE373676T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11221798P 1998-12-14 1998-12-14
GBGB9919676.8A GB9919676D0 (en) 1999-08-19 1999-08-19 Methods

Publications (1)

Publication Number Publication Date
ATE373676T1 true ATE373676T1 (de) 2007-10-15

Family

ID=26315862

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99961205T ATE373676T1 (de) 1998-12-14 1999-12-14 Verfahren zur aktivierung von sgk durch phosphorylierung.

Country Status (5)

Country Link
EP (1) EP1141003B9 (de)
JP (1) JP2002533063A (de)
AT (1) ATE373676T1 (de)
DE (1) DE69937159T2 (de)
WO (1) WO2000035946A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1180151A2 (de) * 1999-05-28 2002-02-20 Sugen, Inc. Proteinkinasen
AU2002223950A1 (en) * 2000-09-20 2002-04-02 Qlt Inc. Cancer associated protein kinases and their uses
US6830925B2 (en) 2000-09-20 2004-12-14 Qlt Inc. CaMK-X1 and its uses
US6933127B2 (en) 2001-07-05 2005-08-23 Eucro European Contract Research Gmbh & Co. Kg Substrate for PP2C
DE10149393A1 (de) * 2001-09-28 2003-04-24 Florian Lang sgk1 als diagnostisches und therapeutisches target
GB0213186D0 (en) 2002-06-08 2002-07-17 Univ Dundee Methods
JP2004018524A (ja) * 2002-06-13 2004-01-22 Eucro European Contract Research Gmbh & Co Kg 動脈硬化症を処置するための方法
DE10305212A1 (de) * 2003-02-07 2004-08-19 Florian Prof. Dr.med. Lang Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom
DE10305213A1 (de) * 2003-02-07 2004-08-26 Florian Prof. Dr.med. Lang Verwendung eines neuen Polymorphismus im hsgk1-Gen zur Diagnose der Hypertonie und Verwendung der sgk-Genfamilie zur Diagnose und Therapie des Long-Q/T-Syndroms
US20050053565A1 (en) * 2003-09-09 2005-03-10 Florian Lang Modulation of hair growth via SGK3
MXPA06010268A (es) * 2004-03-11 2007-04-23 Merck Patent Gmbh Metodos para modular receptores de glutamato para tratar trastornos neuropsiquiatricos, que comprenden el uso de moduladores de cinasas sericas e inducibles con glucocorticoides.
WO2005118832A2 (en) * 2004-06-01 2005-12-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase-like protein (sgkl)
DE102004059781A1 (de) * 2004-12-10 2006-06-22 Sanofi-Aventis Deutschland Gmbh Verwendung der Serum-/Glucocorticoid regulierten Kinase
WO2007037560A1 (ja) * 2005-09-30 2007-04-05 Link Genomics, Inc. Ｓｇｋ２遺伝子の治療的又は診断的用途
WO2008116032A1 (en) * 2007-03-21 2008-09-25 Effat Emamian Compositions and methods for inhibiting tumor cell growth
KR20210008193A (ko) * 2019-07-10 2021-01-21 한양대학교 산학협력단 염증성 신경 질환의 치료제로서 Sgk1 저해제의 용도

Also Published As

Publication number Publication date
JP2002533063A (ja) 2002-10-08
DE69937159T2 (de) 2008-06-26
EP1141003B9 (de) 2008-07-02
EP1141003B1 (de) 2007-09-19
WO2000035946A1 (en) 2000-06-22
EP1141003A1 (de) 2001-10-10
DE69937159D1 (de) 2007-10-31

Similar Documents

Publication Publication Date Title
DE69937159D1 (de) Verfahren zur Aktivierung von SGK durch Phosphorylierung.
EP2298814A3 (de) Verfahren zur Quantifizierung der Phosphokinase-Aktivität auf Proteinen
Cohen 11 Muscle Glycogen Synthase
Gilmore et al. Phorbol ester and diacylglycerol induce protein phosphorylation at tyrosine
Petruzzelli et al. Insulin activates a tyrosine-specific protein kinase in extracts of 3T3-L1 adipocytes and human placenta.
Huganir et al. Phosphorylation of the nicotinic acetylcholine receptor by an endogenous tyrosine-specific protein kinase.
Kohno Diverse mitogenic agents induce rapid phosphorylation of a common set of cellular proteins at tyrosine in quiescent mammalian cells.
Rubenstein et al. Calcium‐dependent serine phosphorylation of synaptophysin
Fabbri et al. Export of protein from the endoplasmic reticulum is regulated by a diacylglycerol/phorbol ester binding protein.
IL96473A0 (en) Method of determining an analyte employing a sparingly soluble salt of a heteropoly acid and a suitable agent therefor
Christensen et al. Role of system Gly in glycine transport in monolayer cultures of liver cells
US20100021939A1 (en) Process for detecting enzyme activity in an immunoassay
DE60045586D1 (de) Testverfahren zur messung der phosphorylierung
RU2006126704A (ru) Способы лечения астмы
ES8607262A1 (es) Esteres de aminoacidos y de peptidos cromogenos
Khalil et al. Protein kinase C: a second EC coupling pathway in vascular smooth muscle?
WO2001044497A3 (en) Protein kinase regulation
Treiman et al. 3′, 5′‐Cyclic Adenosine Monophosphate‐and Ca2+‐Calmodulin‐Dependent Endogenous Protein Phosphorylation Activity in Membranes of the Bovine Chromaffin Secretory Vesicles: Identification of Two Phosphorylated Components as Tyrosine Hydroxylase and Protein Kinase Regulatory Subunit Type II
DE69909419D1 (de) Indium-enthaltende Zusammensetzung zur Messung von Proteinspuren
ATE144327T1 (de) Verfahren zur stabilisierung von endogenen, physiologisch aktiven peptiden
DE3667061D1 (en) New protein isolated from blood, process for preparing said protein, antibodies against said new protein, and pharmaceutical compositions containing said protein or said antibodies
ATE365326T1 (de) Verfahren zur analyse der menge an intraabdominalem fettgewebe
Findik et al. Zn2+ enhances protein tyrosine kinase activity of human platelet membranes
Singh et al. Phosphorylation and activation of rabbit skeletal muscle phosphorylase kinase by a cyclic nucleotide-and Ca2+-independent protein kinase.
WO2000056864A3 (en) Methods for altering substrate specificity of phosphoinositide-dependent-protein kinase 1 (pdk1)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties